Canada’s Jamp Creates Dedicated Biosimilars Division
As It Prepares To Launch Alvotech’s Higher-Strength Adalimumab Humira Rival
Canada’s Jamp Pharma has delivered on plans to create a new dedicated biosimilars division as it prepares to launch the recently-approved higher-strength adalimumab biosimilar on which it has partnered with Alvotech.
You may also be interested in...
Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.
The first biosimilar approval stemming from Alvotech’s collaboration with JAMP Pharma in Canada has arrived, with the firms’ Simlandi (adalimumab) biosimilar version of AbbVie’s higher-strength Humira. Celltrion has also announced an approval from Health Canada.
Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.